The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells. / Hansen, Stine Ninel; Ehlers, Natasja Spring; Zhu, Shida; Thomsen, Mathilde Borg Houlberg; Nielsen, Rikke Linnemann; Liu, Dongbing; Wang, Guangbiao; Hou, Yong; Zhang, Xiuqing; Xu, Xun; Bolund, Lars; Yang, Huanming; Wang, Jun; Moreira, José; Ditzel, Henrik Jørn; Brünner, Nils; Rasmussen, Anne-Sofie Schrohl; Stenvang, Jan; Gupta, Ramneek.

In: B M C Genomics, Vol. 17, 442, 09.06.2016.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Hansen, SN, Ehlers, NS, Zhu, S, Thomsen, MBH, Nielsen, RL, Liu, D, Wang, G, Hou, Y, Zhang, X, Xu, X, Bolund, L, Yang, H, Wang, J, Moreira, J, Ditzel, HJ, Brünner, N, Rasmussen, A-SS, Stenvang, J & Gupta, R 2016, 'The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells' B M C Genomics, vol. 17, 442. https://doi.org/10.1186/s12864-016-2749-4

APA

Hansen, S. N., Ehlers, N. S., Zhu, S., Thomsen, M. B. H., Nielsen, R. L., Liu, D., ... Gupta, R. (2016). The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells. B M C Genomics, 17, [442]. https://doi.org/10.1186/s12864-016-2749-4

Vancouver

Hansen SN, Ehlers NS, Zhu S, Thomsen MBH, Nielsen RL, Liu D et al. The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells. B M C Genomics. 2016 Jun 9;17. 442. https://doi.org/10.1186/s12864-016-2749-4

Author

Hansen, Stine Ninel ; Ehlers, Natasja Spring ; Zhu, Shida ; Thomsen, Mathilde Borg Houlberg ; Nielsen, Rikke Linnemann ; Liu, Dongbing ; Wang, Guangbiao ; Hou, Yong ; Zhang, Xiuqing ; Xu, Xun ; Bolund, Lars ; Yang, Huanming ; Wang, Jun ; Moreira, José ; Ditzel, Henrik Jørn ; Brünner, Nils ; Rasmussen, Anne-Sofie Schrohl ; Stenvang, Jan ; Gupta, Ramneek. / The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells. In: B M C Genomics. 2016 ; Vol. 17.

Bibtex

@article{4d9c1a7f3cb64835b7303b953681c9f9,
title = "The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells",
abstract = "Background: Resistance to taxane-based therapy in breast cancer patients is a major clinical problem that may be addressed through insight of the genomic alterations leading to taxane resistance in breast cancer cells. In the current study we used whole exome sequencing to discover somatic genomic alterations, evolving across evolutionary stages during the acquisition of docetaxel resistance in breast cancer cell lines.Results: Two human breast cancer in vitro models (MCF-7 and MDA-MB-231) of the step-wise acquisition of docetaxel resistance were developed by exposing cells to 18 gradually increasing concentrations of docetaxel. Whole exome sequencing performed at five successive stages during this process was used to identify single point mutational events, insertions/deletions and copy number alterations associated with the acquisition of docetaxel resistance. Acquired coding variation undergoing positive selection and harboring characteristics likely to be functional were further prioritized using network-based approaches. A number of genomic changes were found to be undergoing evolutionary selection, some of which were likely to be functional. Of the five stages of progression toward resistance, most resistance relevant genomic variation appeared to arise midway towards fully resistant cells corresponding to passage 31 (5 nM docetaxel) for MDA-MB-231 and passage 16 (1.2 nM docetaxel) for MCF-7, and where the cells also exhibited a period of reduced growth rate or arrest, respectively. MCF-7 cell acquired several copy number gains on chromosome 7, including ABC transporter genes, including ABCB1 and ABCB4, as well as DMTF1, CLDN12, CROT, and SRI. For MDA-MB-231 numerous copy number losses on chromosome X involving more than 30 genes was observed. Of these genes, CASK, POLA1, PRDX4, MED14 and PIGA were highly prioritized by the applied network-based gene ranking approach. At higher docetaxel concentration MCF-7 subclones exhibited a copy number loss in E2F4, and the gene encoding this important transcription factor was down-regulated in MCF-7 resistant cells.Conclusions: Our study of the evolution of acquired docetaxel resistance identified several genomic changes that might explain development of docetaxel resistance. Interestingly, the most relevant resistance-associated changes appeared to originate midway through the evolution towards fully resistant cell lines. Our data suggest that no single genomic event sufficiently predicts resistance to docetaxel, but require genomic alterations affecting multiple pathways that in concert establish the final resistance stage.",
keywords = "Breast cancer, Docetaxel resistance, Taxane, Exome sequencing",
author = "Hansen, {Stine Ninel} and Ehlers, {Natasja Spring} and Shida Zhu and Thomsen, {Mathilde Borg Houlberg} and Nielsen, {Rikke Linnemann} and Dongbing Liu and Guangbiao Wang and Yong Hou and Xiuqing Zhang and Xun Xu and Lars Bolund and Huanming Yang and Jun Wang and Jos{\'e} Moreira and Ditzel, {Henrik J{\o}rn} and Nils Br{\"u}nner and Rasmussen, {Anne-Sofie Schrohl} and Jan Stenvang and Ramneek Gupta",
year = "2016",
month = "6",
day = "9",
doi = "10.1186/s12864-016-2749-4",
language = "English",
volume = "17",
journal = "B M C Genomics",
issn = "1471-2164",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells

AU - Hansen, Stine Ninel

AU - Ehlers, Natasja Spring

AU - Zhu, Shida

AU - Thomsen, Mathilde Borg Houlberg

AU - Nielsen, Rikke Linnemann

AU - Liu, Dongbing

AU - Wang, Guangbiao

AU - Hou, Yong

AU - Zhang, Xiuqing

AU - Xu, Xun

AU - Bolund, Lars

AU - Yang, Huanming

AU - Wang, Jun

AU - Moreira, José

AU - Ditzel, Henrik Jørn

AU - Brünner, Nils

AU - Rasmussen, Anne-Sofie Schrohl

AU - Stenvang, Jan

AU - Gupta, Ramneek

PY - 2016/6/9

Y1 - 2016/6/9

N2 - Background: Resistance to taxane-based therapy in breast cancer patients is a major clinical problem that may be addressed through insight of the genomic alterations leading to taxane resistance in breast cancer cells. In the current study we used whole exome sequencing to discover somatic genomic alterations, evolving across evolutionary stages during the acquisition of docetaxel resistance in breast cancer cell lines.Results: Two human breast cancer in vitro models (MCF-7 and MDA-MB-231) of the step-wise acquisition of docetaxel resistance were developed by exposing cells to 18 gradually increasing concentrations of docetaxel. Whole exome sequencing performed at five successive stages during this process was used to identify single point mutational events, insertions/deletions and copy number alterations associated with the acquisition of docetaxel resistance. Acquired coding variation undergoing positive selection and harboring characteristics likely to be functional were further prioritized using network-based approaches. A number of genomic changes were found to be undergoing evolutionary selection, some of which were likely to be functional. Of the five stages of progression toward resistance, most resistance relevant genomic variation appeared to arise midway towards fully resistant cells corresponding to passage 31 (5 nM docetaxel) for MDA-MB-231 and passage 16 (1.2 nM docetaxel) for MCF-7, and where the cells also exhibited a period of reduced growth rate or arrest, respectively. MCF-7 cell acquired several copy number gains on chromosome 7, including ABC transporter genes, including ABCB1 and ABCB4, as well as DMTF1, CLDN12, CROT, and SRI. For MDA-MB-231 numerous copy number losses on chromosome X involving more than 30 genes was observed. Of these genes, CASK, POLA1, PRDX4, MED14 and PIGA were highly prioritized by the applied network-based gene ranking approach. At higher docetaxel concentration MCF-7 subclones exhibited a copy number loss in E2F4, and the gene encoding this important transcription factor was down-regulated in MCF-7 resistant cells.Conclusions: Our study of the evolution of acquired docetaxel resistance identified several genomic changes that might explain development of docetaxel resistance. Interestingly, the most relevant resistance-associated changes appeared to originate midway through the evolution towards fully resistant cell lines. Our data suggest that no single genomic event sufficiently predicts resistance to docetaxel, but require genomic alterations affecting multiple pathways that in concert establish the final resistance stage.

AB - Background: Resistance to taxane-based therapy in breast cancer patients is a major clinical problem that may be addressed through insight of the genomic alterations leading to taxane resistance in breast cancer cells. In the current study we used whole exome sequencing to discover somatic genomic alterations, evolving across evolutionary stages during the acquisition of docetaxel resistance in breast cancer cell lines.Results: Two human breast cancer in vitro models (MCF-7 and MDA-MB-231) of the step-wise acquisition of docetaxel resistance were developed by exposing cells to 18 gradually increasing concentrations of docetaxel. Whole exome sequencing performed at five successive stages during this process was used to identify single point mutational events, insertions/deletions and copy number alterations associated with the acquisition of docetaxel resistance. Acquired coding variation undergoing positive selection and harboring characteristics likely to be functional were further prioritized using network-based approaches. A number of genomic changes were found to be undergoing evolutionary selection, some of which were likely to be functional. Of the five stages of progression toward resistance, most resistance relevant genomic variation appeared to arise midway towards fully resistant cells corresponding to passage 31 (5 nM docetaxel) for MDA-MB-231 and passage 16 (1.2 nM docetaxel) for MCF-7, and where the cells also exhibited a period of reduced growth rate or arrest, respectively. MCF-7 cell acquired several copy number gains on chromosome 7, including ABC transporter genes, including ABCB1 and ABCB4, as well as DMTF1, CLDN12, CROT, and SRI. For MDA-MB-231 numerous copy number losses on chromosome X involving more than 30 genes was observed. Of these genes, CASK, POLA1, PRDX4, MED14 and PIGA were highly prioritized by the applied network-based gene ranking approach. At higher docetaxel concentration MCF-7 subclones exhibited a copy number loss in E2F4, and the gene encoding this important transcription factor was down-regulated in MCF-7 resistant cells.Conclusions: Our study of the evolution of acquired docetaxel resistance identified several genomic changes that might explain development of docetaxel resistance. Interestingly, the most relevant resistance-associated changes appeared to originate midway through the evolution towards fully resistant cell lines. Our data suggest that no single genomic event sufficiently predicts resistance to docetaxel, but require genomic alterations affecting multiple pathways that in concert establish the final resistance stage.

KW - Breast cancer

KW - Docetaxel resistance

KW - Taxane

KW - Exome sequencing

U2 - 10.1186/s12864-016-2749-4

DO - 10.1186/s12864-016-2749-4

M3 - Journal article

VL - 17

JO - B M C Genomics

JF - B M C Genomics

SN - 1471-2164

M1 - 442

ER -

ID: 165747365